~~<i id='18EA69BEFC'><strike id='18EA69BEFC'><tt id='18EA69BEFC'><pre id='18EA69BEFC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：leisure time 2025-09-29 01:38:05 - browse：98333

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Congress considering partial increase for doctor pay in Medicare

focus

leisure time

entertainment

hotspot

Congressisdebatingincreasingdoctors'Medicarepay,butnotbringingituptolastyear'slevels.AlexWong/GettyI

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Medicare Advantage enrollment hits roughly 33.4 million

A new drug could help frostbite victims avoid its ravages

Tome Biosciences co

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Surprise medical billing ban raises prices elsewhere

hotspot

leisure time

focus

In Memoriam: Notable people who died in 2023

Medicare Advantage enrollment grows 7.1% to 33.4 million people

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA warns medical device makers about rise in fabricated data

Cancer drug shortages should be causing more outrage

Study gives hint on South Asians’ higher risk of cardiovascular disease

Virginia high school admissions case could be legal follow

Medicare Advantage enrollment grows 7.1% to 33.4 million people

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

focus

New CMS data security rules will hurt Medicare, Medicaid research

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Why don't Americans have at

A new drug could help frostbite victims avoid its ravages

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

focus

leisure time

entertainment

hotspot